Drug · CHEMBL807

MEMANTINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. MEMANTINE. Drugs and targets, record CHEMBL807. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL807

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: MEMANTINE; ChEMBL
ChEMBL ID: CHEMBL807; ChEMBL
Type: Small molecule; ChEMBL
Other names: D-145, DRG-0267, Memantina, NSC-757843; ChEMBL
Other form: MEMANTINE HYDROCHLORIDE, CHEMBL1699; Drugs and targets
DrugBank: DB01043; DrugBank
InChIKey: BUGYDGFZZOZRHP-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 62 diseases, from ATC, EMA Human Drugs and TTD; Open Targets

Targets7

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GRIN1	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2902
GRIN2A	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2903
GRIN2B	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2904
GRIN2C	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2905
GRIN2D	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2906
GRIN3A	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/116443
GRIN3B	Glutamate [NMDA] receptor	Glutamate [NMDA] receptor negative allosteric modulator	NEGATIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/116444

Source ChEMBL

Diseases62

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Alzheimer disease	Approval	EMA Human Drugs and TTD	48	38	https://conductscience.org/library/drugs?q=MONDO_0004975
Cognitive impairment	Phase 3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=HP_0100543
schizophrenia	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0005090
autism spectrum disorder	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0005258
amyotrophic lateral sclerosis	Phase 2/3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0004976
autism	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005260
major depressive disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0002009
obsessive-compulsive disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0008114
dementia	Approval	ATC	5	4	https://conductscience.org/library/drugs?q=MONDO_0001627
Parkinson disease	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005180

1 to 10 of 62Source Open Targets

See all 62 diseases

Trials208

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01592786	An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Phase 2	906	2014-08-07	memantine	Its name	ClinicalTrials.gov
NCT00322153	A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease	Phase 3	677	2010-09-16	memantine	Its name	ClinicalTrials.gov
NCT00235716	A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	Phase 3	613	2014-01-29	memantine	Its name	ClinicalTrials.gov
NCT01592747	Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine	Phase 2	479	2019-04-24	memantine	Its name	ClinicalTrials.gov
NCT00857649	Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease	Phase 3	369	2012-01-09	memantine	Its name	ClinicalTrials.gov
NCT00857233	Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease	Phase 3	297	2012-08-29	memantine	Its name	ClinicalTrials.gov
NCT00862940	A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease	Phase 4	277	2011-06-03	memantine	Its name	ClinicalTrials.gov
NCT00469456	Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease	Phase 4	265	2009-12-07	memantine	Its name	ClinicalTrials.gov
NCT04117178	Monitoring Anti-Dementia Drugs by Serum Levels	Phase 4	132	2025-02-10	memantine	Its name	ClinicalTrials.gov
NCT00872898	Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism	Phase 2	124	2014-01-14	memantine	Its name	ClinicalTrials.gov

1 to 10 of 208

See all 208 trials

Comparisons in its trials74

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Memantine ER vs Placebo: serious adverse events	28 of 341	21 of 335	676	NCT00322153	Trial comparisons
Memantine vs Placebo: serious adverse events	18 of 182	11 of 187	369	NCT00857649	Trial comparisons
Memantine 10 mg Tablets Twice Daily vs Placebo Tablets Twice Daily: serious adverse events	17 of 133	20 of 144	277	NCT00862940	Trial comparisons
Memantine vs Placebo: serious adverse events	4 of 135	13 of 129	264	NCT00469456	Trial comparisons
Memantine vs Placebo: deaths from any cause	0 of 80	0 of 80	160	NCT01555697	Trial comparisons
Memantine vs Placebo: serious adverse events	0 of 80	0 of 80	160	NCT01555697	Trial comparisons
Intervention Arm vs Standard of Care: deaths from any cause	2 of 67	2 of 65	132	NCT04117178	Trial comparisons
Intervention Arm vs Standard of Care: serious adverse events	7 of 67	6 of 65	132	NCT04117178	Trial comparisons
Memantine to Memantine vs Placebo to Memantine: serious adverse events	0 of 52	1 of 50	102	NCT01999894	Trial comparisons
Memantine vs Placebo: deaths from any cause	0 of 55	0 of 45	100	NCT04792645	Trial comparisons

1 to 10 of 74

See all 74 comparisons in its trials

Papers from its trials97

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31447547	RESULT	1	PubMed
31169568	RESULT	2	PubMed
29100251	RESULT	1	PubMed
28705532	RESULT	1	PubMed
27249077	RESULT	1	PubMed
27050431	RESULT	1	PubMed
25465228	RESULT	1	PubMed
24381967	RESULT	1	PubMed
23525525	RESULT	1	PubMed
23472619	RESULT	1	PubMed

1 to 10 of 97

See all 97 papers from its trials

Tests in its trials39

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Verbal Learning	16	11	ConductCognition
Trail Making Test A	13	2	ConductCognition
Verbal Fluency	13	2	ConductCognition
Trail Making Test B	11	1	ConductCognition
Card Sorting Test (Berg)	6	1	ConductCognition
Category Fluency	4	0	ConductCognition
Continuous Performance Test	4	1	ConductCognition
Stroop Color-Word Test	4	1	ConductCognition
Digit Span Test	3	0	ConductCognition
Symbol Coding	3	0	ConductCognition

1 to 10 of 39

See all 39 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL807

GET https://conductscience.org/api/drugs/v1/CHEMBL807/diseases?page=2

API reference For AI assistants